After the December results, analysts have been bullish on the stock of CYTK.
Roanna Ruiz, an analyst at Leerink Partners, noted that only 3.5% of patients in the Sequoia study conducted by Cytokinetics had a low ventricular ejection fraction, or LVEF. Furthermore, none of them opted out. LVEF happens when a portion of the heart isn’t siphoning sufficient blood, as indicated by the American Heart Affiliation.
In a report published on December 27, she stated, “All in all, we think the data could provide a path for higher clinical uptake than we previously expected, including (an) incrementally raised possibility of aficamten receiving a less restrictive (risk evaluation and mitigation strategies plan) relative to Camzyos.” Ruiz retained her CYTK stock outperform rating.